AR089776A1 - 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir - Google Patents
5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/irInfo
- Publication number
- AR089776A1 AR089776A1 ARP130100189A ARP130100189A AR089776A1 AR 089776 A1 AR089776 A1 AR 089776A1 AR P130100189 A ARP130100189 A AR P130100189A AR P130100189 A ARP130100189 A AR P130100189A AR 089776 A1 AR089776 A1 AR 089776A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- phenyl
- indicates
- halogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 6
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100518413 Caenorhabditis elegans orc-2 gene Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12152193 | 2012-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089776A1 true AR089776A1 (es) | 2014-09-17 |
Family
ID=47605520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100189A AR089776A1 (es) | 2012-01-23 | 2013-01-22 | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9150578B2 (enExample) |
| EP (1) | EP2807166B1 (enExample) |
| JP (1) | JP6128133B2 (enExample) |
| AR (1) | AR089776A1 (enExample) |
| TW (1) | TW201343648A (enExample) |
| UY (1) | UY34586A (enExample) |
| WO (1) | WO2013110585A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017003651A2 (pt) * | 2014-09-02 | 2017-12-05 | Pf Medicament | derivados de isoquinolinona úteis no tratamento de câncer |
| WO2016180843A1 (en) * | 2015-05-13 | 2016-11-17 | Boehringer Ingelheim International Gmbh | New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2- yl)-(1 h-pyrazol-3-yl)-amines and derivatives as igf-1 r/ir inhibitors |
| KR102464677B1 (ko) * | 2017-08-11 | 2022-11-10 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| JP2022545835A (ja) | 2019-08-28 | 2022-10-31 | ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー | 甲状腺眼症の治療方法 |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| AU2023216263A1 (en) * | 2022-02-04 | 2024-08-22 | Mrja Therapeutics, Inc. | Certain chemical entities, compositions, and methods |
| WO2024153237A1 (zh) * | 2023-01-19 | 2024-07-25 | 北京普祺医药科技股份有限公司 | 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途 |
| WO2024153226A1 (zh) * | 2023-01-19 | 2024-07-25 | 北京普祺医药科技股份有限公司 | 一种吡唑并环类化合物、药物组合物及其用途 |
| CN116458513A (zh) * | 2023-05-08 | 2023-07-21 | 广东方中高新材料有限公司 | 一种含镓配合物的咪鲜胺增效水乳制剂及其制备方法 |
| CN116473073A (zh) * | 2023-05-08 | 2023-07-25 | 广东方中高新材料有限公司 | 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法 |
| CN116473077B (zh) * | 2023-05-08 | 2025-04-11 | 广东方中高新材料有限公司 | 一种n,n配位的镓配合物抗菌剂的合成和应用 |
| CN122003247A (zh) | 2023-07-07 | 2026-05-08 | 维里迪安治疗公司 | 治疗活动性和慢性甲状腺眼病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450769A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| US7348335B2 (en) | 2002-11-05 | 2008-03-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| ES2436524T3 (es) * | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
| US20050075358A1 (en) | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| PL2027123T3 (pl) * | 2006-05-11 | 2011-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
-
2013
- 2013-01-22 EP EP13701426.2A patent/EP2807166B1/en active Active
- 2013-01-22 AR ARP130100189A patent/AR089776A1/es unknown
- 2013-01-22 WO PCT/EP2013/051097 patent/WO2013110585A1/en not_active Ceased
- 2013-01-22 US US13/746,411 patent/US9150578B2/en active Active
- 2013-01-22 JP JP2014552655A patent/JP6128133B2/ja active Active
- 2013-01-22 TW TW102102378A patent/TW201343648A/zh unknown
- 2013-01-23 UY UY0001034586A patent/UY34586A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013110585A1 (en) | 2013-08-01 |
| US9150578B2 (en) | 2015-10-06 |
| EP2807166A1 (en) | 2014-12-03 |
| JP6128133B2 (ja) | 2017-05-17 |
| EP2807166B1 (en) | 2016-04-06 |
| UY34586A (es) | 2013-09-02 |
| JP2015504081A (ja) | 2015-02-05 |
| US20130190305A1 (en) | 2013-07-25 |
| TW201343648A (zh) | 2013-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR097436A1 (es) | Bis-amidopiridinas | |
| UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| AR098337A1 (es) | Triazolopirazina | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| MX373711B (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR087913A1 (es) | Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c | |
| MX2015009950A (es) | Compuestos de imidazopiridina y sus usos. | |
| AR090994A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| AR097435A1 (es) | 6-alquinilpiridinas | |
| AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
| AR082850A1 (es) | Aminopirazoloquinazolinas | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |